Hundreds of children living with spinal muscular atrophy (SMA) in England are now eligible to receive two innovative and potentially “life-changing” therapies on the NHS. From today, nusinersen and risdiplam will be routinely available, offering long-term certainty to families navigating this rare and severe muscle-wasting condition. This decision follows an access scheme designed to gather further evidence on the treatments' effectiveness in a real-world setting.
Spinal muscular atrophy is a genetic condition that causes progressive muscle weakness and loss of movement. It affects approximately one in 10,000 babies born in the UK, making it one of the most common genetic causes of death in infants. The severity of SMA varies, but without treatment, children with the most severe form often do not live beyond early childhood, while others may experience significant physical disability.
The introduction of nusinersen (also known as Spinraza) and risdiplam (Evrysdi) marks a significant advancement in the treatment of SMA. Nusinersen, administered via injection into the fluid surrounding the spinal cord, works by increasing the production of a protein essential for motor neuron function. Risdiplam, an oral medication, works in a similar way and offers a less invasive administration route, which can be particularly beneficial for younger children or those with complex needs.
Clinical trials and real-world data from the access scheme have demonstrated that these therapies can significantly alter the natural progression of SMA. Benefits include improved motor function, the ability to sit independently, and even walk in some cases, with the potential to extend lifespans and enable children to reach developmental milestones such as attending primary school. This represents a profound shift from the historical prognosis for many children with SMA.
The routine availability of these treatments on the NHS provides reassurance for families who have previously faced uncertainty regarding long-term access. This move aligns with NICE (National Institute for Health and Care Excellence) recommendations, which have previously endorsed these treatments under managed access agreements. The expansion of eligibility ensures that a broader cohort of children can now benefit from these crucial interventions, offering hope for improved quality of life and future prospects.